JP2004532883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532883A5 JP2004532883A5 JP2003501455A JP2003501455A JP2004532883A5 JP 2004532883 A5 JP2004532883 A5 JP 2004532883A5 JP 2003501455 A JP2003501455 A JP 2003501455A JP 2003501455 A JP2003501455 A JP 2003501455A JP 2004532883 A5 JP2004532883 A5 JP 2004532883A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- rapamycin
- tumor
- mtor inhibitor
- alkylating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940124302 mTOR inhibitor Drugs 0.000 claims 10
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 10
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 10
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 10
- 229960002930 sirolimus Drugs 0.000 claims 10
- 229940100198 alkylating agent Drugs 0.000 claims 8
- 239000002168 alkylating agent Substances 0.000 claims 8
- 230000000259 anti-tumor effect Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 4
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 4
- 229960000235 temsirolimus Drugs 0.000 claims 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 2
- 229930192392 Mitomycin Natural products 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 2
- 229960002092 busulfan Drugs 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- 229960004630 chlorambucil Drugs 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- HKVAMNSJSFKALM-CPXURSODSA-N everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C\C=C\C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-CPXURSODSA-N 0.000 claims 2
- 229960002247 lomustine Drugs 0.000 claims 2
- 229960001924 melphalan Drugs 0.000 claims 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960000624 procarbazine Drugs 0.000 claims 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 229960001196 thiotepa Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- -1 ifostamide Chemical compound 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000028830 lung neuroendocrine neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29519001P | 2001-06-01 | 2001-06-01 | |
| US29523601P | 2001-06-01 | 2001-06-01 | |
| PCT/US2002/016737 WO2002098416A2 (en) | 2001-06-01 | 2002-05-29 | Antineoplastic combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004532883A JP2004532883A (ja) | 2004-10-28 |
| JP2004532883A5 true JP2004532883A5 (enExample) | 2006-01-05 |
Family
ID=26968972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003501455A Withdrawn JP2004532883A (ja) | 2001-06-01 | 2002-05-29 | 抗腫瘍コンビネーション |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1392286A2 (enExample) |
| JP (1) | JP2004532883A (enExample) |
| KR (1) | KR100875611B1 (enExample) |
| CN (1) | CN100496485C (enExample) |
| AU (2) | AU2002259309B2 (enExample) |
| BR (1) | BR0210101A (enExample) |
| CA (1) | CA2447732A1 (enExample) |
| CO (1) | CO5540294A2 (enExample) |
| EA (1) | EA007530B1 (enExample) |
| HU (1) | HUP0400006A2 (enExample) |
| IL (1) | IL158800A0 (enExample) |
| MX (1) | MXPA03010907A (enExample) |
| NO (1) | NO20035317L (enExample) |
| NZ (1) | NZ529877A (enExample) |
| PL (1) | PL367267A1 (enExample) |
| SG (1) | SG153647A1 (enExample) |
| WO (1) | WO2002098416A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1551767A (zh) | 2001-02-19 | 2004-12-01 | ��˹��ŵ�� | 癌症的治疗 |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| AR046194A1 (es) | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
| NZ556673A (en) | 2005-02-03 | 2010-03-26 | Gen Hospital Corp | Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor |
| EP3488866A1 (en) * | 2005-11-04 | 2019-05-29 | Wyeth LLC | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| PT2275103E (pt) * | 2005-11-21 | 2014-07-24 | Novartis Ag | Inibidores de mtor para o tratamento de tumores endócrinos |
| US20090023768A1 (en) * | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
| CA2645633A1 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| EP3417859A1 (en) * | 2007-03-07 | 2018-12-26 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| ES2531322T3 (es) | 2008-06-17 | 2015-03-13 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| EP3175853B1 (en) | 2008-08-04 | 2023-11-01 | Wyeth LLC | Antineoplastic combinations of neratinib and capecitabine |
| PT3000467T (pt) | 2009-04-06 | 2023-03-30 | Wyeth Llc | Regime de tratamento utilizando neratinib para o cancro de mama |
| CN103721189A (zh) * | 2013-12-27 | 2014-04-16 | 刘玉含 | 一种脑膜瘤护理药物及其制备方法 |
| CN105168204A (zh) * | 2015-09-06 | 2015-12-23 | 江志鑫 | 一种含有丝裂霉素的抗结肠癌药物组合物 |
| CN119732959A (zh) * | 2024-12-31 | 2025-04-01 | 吉林大学 | 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| DE69209183T2 (de) * | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
| TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| CN1551767A (zh) * | 2001-02-19 | 2004-12-01 | ��˹��ŵ�� | 癌症的治疗 |
-
2002
- 2002-05-29 PL PL02367267A patent/PL367267A1/xx not_active Application Discontinuation
- 2002-05-29 EA EA200301319A patent/EA007530B1/ru not_active IP Right Cessation
- 2002-05-29 CN CNB02811048XA patent/CN100496485C/zh not_active Expired - Fee Related
- 2002-05-29 NZ NZ529877A patent/NZ529877A/en unknown
- 2002-05-29 EP EP02729310A patent/EP1392286A2/en not_active Ceased
- 2002-05-29 JP JP2003501455A patent/JP2004532883A/ja not_active Withdrawn
- 2002-05-29 WO PCT/US2002/016737 patent/WO2002098416A2/en not_active Ceased
- 2002-05-29 MX MXPA03010907A patent/MXPA03010907A/es not_active Application Discontinuation
- 2002-05-29 KR KR1020037015721A patent/KR100875611B1/ko not_active Expired - Fee Related
- 2002-05-29 SG SG200507698-9A patent/SG153647A1/en unknown
- 2002-05-29 AU AU2002259309A patent/AU2002259309B2/en not_active Ceased
- 2002-05-29 HU HU0400006A patent/HUP0400006A2/hu unknown
- 2002-05-29 BR BR0210101-7A patent/BR0210101A/pt not_active Application Discontinuation
- 2002-05-29 IL IL15880002A patent/IL158800A0/xx unknown
- 2002-05-29 CA CA002447732A patent/CA2447732A1/en not_active Abandoned
-
2003
- 2003-11-26 CO CO03104435A patent/CO5540294A2/es not_active Application Discontinuation
- 2003-11-28 NO NO20035317A patent/NO20035317L/no not_active Application Discontinuation
-
2008
- 2008-06-18 AU AU2008202690A patent/AU2008202690A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006519862A5 (enExample) | ||
| IL159859A (en) | Antineoplastic combinations | |
| JP2006524246A5 (enExample) | ||
| JP2008528671A5 (enExample) | ||
| JP5931982B2 (ja) | （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物 | |
| JP2023515235A5 (enExample) | ||
| JP2004525950A5 (enExample) | ||
| JP2023542066A5 (enExample) | ||
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| RU2005136222A (ru) | Противоопухолевые комбинации | |
| JP2019510832A5 (enExample) | ||
| JP6648040B2 (ja) | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 | |
| WO2005097107A8 (en) | Diphenyl - indol-2-on compounds and their use in the treatment of cancer | |
| JP2008535902A5 (enExample) | ||
| JP2023545096A5 (enExample) | ||
| RU2007134396A (ru) | Химические соединения | |
| BG108072A (en) | The use of epothilone derivatives for the treatment of refractory tumors | |
| TW200407326A (en) | Pyrimido compounds having antiproliferative activity | |
| TW200519111A (en) | N3-substituted imidazopyridine C-KIT inhibitors | |
| TW200633704A (en) | N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library | |
| CA2447021A1 (en) | Pyridyl cyanoguanidine compounds | |
| JP2024515809A5 (enExample) | ||
| JP2013511526A5 (enExample) | ||
| JP2008508287A5 (enExample) | ||
| JP2007277240A5 (enExample) |